Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.

Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, Gandolini G, Gnessi L, Laurenzi M, Lombardi A, et al.

Bone. 1995 Oct;17(4):383-90.

PMID:
8573412
2.

An overview of the results of clinical trials with alendronate, a promising treatment of osteoporosis in postmenopausal women.

Hirsch LJ, Pryor-Tillotson S.

Ann Ital Med Int. 1995 Oct;10 Suppl:22S-28S. Review.

PMID:
8562261
4.

Treatment for osteoporosis in people with ß-thalassaemia.

Bhardwaj A, Swe KM, Sinha NK, Osunkwo I.

Cochrane Database Syst Rev. 2016 Mar 10;3:CD010429. doi: 10.1002/14651858.CD010429.pub2. Review.

PMID:
26964506
5.

Pharmacodynamics and pharmacokinetics of oral salmon calcitonin in the treatment of osteoporosis.

Bandeira L, Lewiecki EM, Bilezikian JP.

Expert Opin Drug Metab Toxicol. 2016 Jun;12(6):681-9. doi: 10.1080/17425255.2016.1175436. Epub 2016 Apr 18. Review.

PMID:
27070719
6.

Calcitonin intranasal--unigene: Salcatonin intranasal--unigene.

[No authors listed]

Drugs R D. 2004;5(2):90-3. Review.

PMID:
15293868
7.

Effect of nasal salmon calcitonin on calcium and bone metabolism.

Thamsborg G.

Dan Med Bull. 1999 Apr;46(2):118-26. Review.

PMID:
10327295
8.

Salmon calcitonin: a review of current and future therapeutic indications.

Chesnut CH 3rd, Azria M, Silverman S, Engelhardt M, Olson M, Mindeholm L.

Osteoporos Int. 2008 Apr;19(4):479-91. Epub 2007 Dec 11. Review.

PMID:
18071651
9.

Oral salmon calcitonin--pharmacology in osteoporosis.

Henriksen K, Bay-Jensen AC, Christiansen C, Karsdal MA.

Expert Opin Biol Ther. 2010 Nov;10(11):1617-29. doi: 10.1517/14712598.2010.526104. Epub 2010 Oct 11. Review.

PMID:
20932224
10.

Osteoporosis prevention and treatment.

Bellantoni MF.

Am Fam Physician. 1996 Sep 1;54(3):986-92, 995-6. Review.

PMID:
8784169
11.

Bone mineral density reflects bone mass but also the degree of mineralization of bone: therapeutic implications.

Meunier PJ, Boivin G.

Bone. 1997 Nov;21(5):373-7. Review. No abstract available.

PMID:
9356729
12.

Esophagitis associated with the use of alendronate.

de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK.

N Engl J Med. 1996 Oct 3;335(14):1016-21. Review.

13.

Salmon calcitonin use and associated cancer risk.

Overman RA, Borse M, Gourlay ML.

Ann Pharmacother. 2013 Dec;47(12):1675-84. doi: 10.1177/1060028013509233. Epub 2013 Oct 25. Review.

PMID:
24259626

Supplemental Content

Support Center